Regulatory Affairs Professionals Society

Recon: FDA approves Egetis’ Emcitate for rare genetic disease; Novo buys rights to Chinese weight-loss pill in $2.6B deal

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
Regulatory Affairs Professionals Society

Convergence: Regulators highlight efforts to streamline the European regulatory framework

A panel of regulators convened at the 2026 RAPS Convergence to discuss several initiatives underway in Europe to help ...
Regulatory Affairs Professionals Society

This Week at FDA: Overton nomination hearing, FDA’s hiring challenges, and more

This week, a Senate committee scheduled a hearing for President Trump’s nominee to lead FDA, new reporting sheds light on the ...
Regulatory Affairs Professionals Society

Recon: FDA staff raise no major concerns for Grail multi-cancer test ahead of adcomm; Trump admin drafting order to exert control over NIH grant funding

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
Regulatory Affairs Professionals Society

Recon: Pharma companies urge Trump administration to protect China deals; EU drugmakers seek faster trials, more spending to compete with US, China

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
RAPS

Euro Roundup: MHRA commission makes recommendations on AI regulatory framework in the UK

A commission set up by the Medicines and Healthcare products Regulatory Agency (MHRA) has shared 44 recommendations about the future regulatory framework for AI in the UK. MHRA created the National ...
Regulatory Affairs Professionals Society

Recon: Senate hearing set for FDA nominee; Novo partners with Anthropic for AI drug development

CHARLOTTE, NC — A panel of experts representing the European Commission, industry, and notified bodies reviewed the state ...
RAPS

Convergence: Thinking past GCP compliance for regulatory acceptability of foreign trial data

CHARLOTTE, NC — Whether the US Food and Drug Administration (FDA) will accept clinical evidence from outside the United States (OUS) depends on if the investigations followed good clinical practice ...
Regulatory Affairs Professionals Society

Recon: Adcomm backs Grail’s cancer test; Lilly, China’s InnoCare sign $3.35B deal

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. In Foc ...
Regulatory Affairs Professionals Society

Convergence: EU officials tout pending pharmaceutical reforms

Officials from the European Commission and European Medicines Agency (EMA) touted key reforms presented in the proposal to ...
RAPS

Euro Roundup: EMA officials argue against making single pivotal trials the ‘rigid, default position’

Emer Cooke and other EMA leaders have weighed into the debate about whether sponsors should run one or two pivotal trials, arguing that the decision should be informed by the evidence needed to show a ...